Unlock AI-driven, actionable R&D insights for your next breakthrough.

Iron Chloride Pharmaceutical Applications: Comprehensive Analysis And Therapeutic Potential

NOV 17, 202660 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Iron chloride compounds, particularly ferric chloride (FeCl₃) and ferrous chloride (FeCl₂), represent a critical class of inorganic salts with emerging pharmaceutical applications spanning cardiovascular therapy, mineral supplementation, and drug delivery systems. Recent advances in iron chelation therapy and bioavailability optimization have positioned iron chloride formulations as essential components in treating iron deficiency disorders and myocardial infarction, while novel synthesis routes from iron phosphate precursors offer sustainable production pathways for pharmaceutical-grade materials 1,5,6.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Physicochemical Properties Of Iron Chloride In Pharmaceutical Contexts

Iron chloride exists primarily in two oxidation states relevant to pharmaceutical applications: ferrous chloride (FeCl₂) and ferric chloride (FeCl₃). Ferrous chloride typically forms tetrahydrate crystals (FeCl₂·4H₂O) with a molecular weight of 198.81 g/mol, exhibiting pale green coloration and high aqueous solubility (64.4 g/100 mL at 20°C). Ferric chloride commonly exists as the hexahydrate (FeCl₃·6H₂O, MW 270.30 g/mol), presenting as yellow-brown deliquescent crystals with exceptional water solubility (92 g/100 mL at 20°C) 5,6. The hygroscopic nature of both compounds necessitates careful storage under inert atmospheres to prevent oxidation and hydrolysis, particularly for ferrous forms which readily oxidize to ferric species in the presence of atmospheric oxygen.

The chemical reactivity of iron chlorides in physiological environments is governed by their Lewis acid character and redox potential. In aqueous media at physiological pH (7.35-7.45), ferric chloride undergoes partial hydrolysis to form polynuclear hydroxo-complexes and colloidal ferric hydroxide, with equilibrium constants highly dependent on chloride ion concentration. This behavior is critical for understanding bioavailability, as the formation of soluble iron-chloro complexes enhances gastrointestinal absorption compared to simple ferric hydroxide precipitates 13. The standard reduction potential for the Fe³⁺/Fe²⁺ couple in chloride media (E° ≈ +0.77 V vs. SHE) positions iron chlorides as moderate oxidizing agents, relevant to their catalytic roles in oxidative stress modulation and potential therapeutic mechanisms in cardiovascular applications 1.

Key physicochemical parameters influencing pharmaceutical formulation include:

  • Thermal stability: Anhydrous FeCl₃ sublimes at 315°C under atmospheric pressure, while FeCl₂ decomposes above 677°C, providing processing windows for spray-drying and thermal sterilization 2,3
  • pH-dependent speciation: At gastric pH (1.5-3.5), iron chlorides remain predominantly as soluble Fe²⁺ and Fe³⁺ aquo-chloro complexes, whereas at intestinal pH (6.5-7.5), hydrolysis and precipitation become significant, necessitating formulation strategies to maintain bioavailable forms 13
  • Chloride ion activity: The presence of exogenous chloride ions (≥100 mM) stabilizes ferric chloride solutions by shifting hydrolysis equilibria and preventing premature precipitation, a principle exploited in oral iron-magnesium combination therapies 13

Pharmaceutical-Grade Synthesis And Purification Methodologies For Iron Chloride

Traditional pharmaceutical-grade iron chloride production involves direct chlorination of metallic iron or dissolution of iron oxides in hydrochloric acid, followed by crystallization and purification steps to achieve USP/EP specifications (typically ≥98% purity, heavy metal content <10 ppm). However, recent patent literature reveals innovative synthesis routes addressing sustainability and feedstock diversification 3,5,6,9.

Novel Synthesis From Iron Phosphate Precursors

A breakthrough process developed by LANXESS Deutschland GmbH describes the production of iron chlorides from iron phosphate compounds, particularly relevant given the increasing availability of lithium iron phosphate (LFP) battery waste streams 5,6. The process comprises:

Step i) Chlorination reaction: Iron phosphate materials (including Fe₃(PO₄)₂, FePO₄, or LiFe₁₋ₓMnₓPO₄ where 0≤x<0.9) are reacted with alkali metal chlorides (NaCl, KCl) or alkaline earth metal chlorides (CaCl₂, MgCl₂) at 200-1100°C in an inert atmosphere (N₂ or Ar with <100 ppm O₂). The reaction proceeds via chloride exchange mechanisms, exemplified by:

2FePO₄ + 3CaCl₂ → 2FeCl₃ + Ca₃(PO₄)₂ (at 600-800°C)

Step ii) Vapor-phase separation: Formed iron chlorides (predominantly FeCl₃, sublimation point 315°C) are volatilized and withdrawn in the off-gas stream, enabling separation from non-volatile phosphate by-products. Condensation at controlled temperatures (150-250°C) yields anhydrous FeCl₃ suitable for pharmaceutical processing 5,6.

This methodology offers several advantages for pharmaceutical applications:

  • Elimination of metallic iron feedstock requirements, reducing heavy metal contamination risks
  • Intrinsic removal of phosphate impurities through vapor-solid phase separation, simplifying purification
  • Compatibility with circular economy principles by valorizing battery recycling streams
  • Scalable operation with reported iron chloride yields exceeding 92% based on iron content 5

Purification Strategies For Pharmaceutical Compliance

Achieving pharmaceutical-grade purity requires removal of trace contaminants, particularly niobium, titanium, and zirconium compounds that co-volatilize during chlorination processes 10. A disclosed purification method involves:

  1. Thermal hydrolysis: Heating crude iron chloride solutions (50-250 g Fe/L) to 120-300°C under autogenous pressure (2-15 bar) to precipitate Nb, Ti, and Zr as insoluble oxychlorides and hydroxides
  2. Solid-liquid separation: Filtration, centrifugation, or settling to remove precipitated impurities, achieving <5 ppm residual Nb/Ti/Zr in the purified FeCl₃ solution
  3. Crystallization: Controlled cooling and evaporation to obtain pharmaceutical-grade FeCl₃·6H₂O crystals meeting USP monograph specifications 10

This process is particularly relevant for iron chloride derived from titanium dioxide production by-products, where titaniferous impurities are prevalent 10,12,16.

Cardiovascular Therapeutic Applications: Iron Chelation And Myocardial Infarction Treatment

A pioneering pharmaceutical application of iron chloride chemistry involves the use of iron chelating agents for treating and preventing myocardial infarction (MI), as disclosed in Japanese Patent Application JP2010215549A 1. The therapeutic rationale centers on modulating iron-catalyzed oxidative stress in ischemic myocardium.

Mechanistic Basis Of Iron Chelation Therapy In MI

During myocardial ischemia-reperfusion injury, intracellular iron released from damaged myocytes catalyzes Fenton reactions, generating highly reactive hydroxyl radicals (·OH) that exacerbate lipid peroxidation, protein oxidation, and DNA damage. The key pathological reaction is:

Fe²⁺ + H₂O₂ → Fe³⁺ + ·OH + OH⁻ (Fenton reaction)

Iron chelators interrupt this cycle by sequestering catalytically active iron species, preventing radical formation. The preferred chelator disclosed is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, which exhibits high affinity for both Fe²⁺ and Fe³⁺ (log K ≈ 20-22), effectively competing with endogenous iron-binding proteins 1.

Formulation And Dosing Strategies

The iron chelator is formulated for oral, parenteral, rectal, or transdermal administration, with active ingredient concentrations ranging from 0.001-100% w/w, preferably 0.1-50% w/w for optimal bioavailability and patient compliance 1. Typical oral formulations comprise:

  • Immediate-release tablets: 50-500 mg chelator per tablet, with hydroxypropyl methylcellulose (HPMC) as binder and microcrystalline cellulose as diluent
  • Sustained-release matrices: Ethylcellulose-coated pellets providing 12-24 hour release kinetics, targeting steady-state plasma concentrations of 5-15 μg/mL
  • Combination therapies: Co-formulation with standard MI treatments (antiplatelet agents, beta-blockers, ACE inhibitors) to provide synergistic cardioprotection 1

Clinical efficacy parameters include reduction in infarct size (measured by cardiac MRI or troponin release kinetics), preservation of left ventricular ejection fraction (LVEF), and decreased incidence of post-MI heart failure. Preclinical studies in rat MI models demonstrated 30-45% reduction in infarct size with chelator treatment initiated within 6 hours of coronary occlusion 1.

Iron And Magnesium Co-Supplementation: Overcoming Bioavailability Challenges With Chloride Optimization

A critical pharmaceutical innovation addresses the long-standing challenge of simultaneous iron and magnesium supplementation, where magnesium compounds traditionally inhibit iron absorption through formation of insoluble complexes in the gastrointestinal tract 13.

Chloride Ion-Mediated Bioavailability Enhancement

Patent USB5147650A discloses an oral pharmaceutical formulation enabling concurrent iron and magnesium therapy without compromising iron bioavailability 13. The key innovation involves providing sufficient chloride ions to saturate magnesium valences, preventing magnesium from complexing with iron or forming absorption-inhibiting precipitates. The formulation comprises:

Component specifications:

  • Iron compounds: Ferrous chloride (FeCl₂·4H₂O), ferrous sulfate (FeSO₄·7H₂O), or ferrous gluconate, providing 50-200 mg elemental iron per dose
  • Magnesium compounds: Magnesium oxide (MgO), magnesium hydroxide (Mg(OH)₂), magnesium aspartate, or magnesium chloride (MgCl₂·6H₂O), providing 100-400 mg elemental magnesium per dose
  • Chloride source: When using chloride-free magnesium compounds, additional chloride is supplied as MgCl₂, CaCl₂, FeCl₂, FeCl₃, KCl, or dilute HCl in quantities providing ≥2 molar equivalents of Cl⁻ per mole of Mg²⁺ 13

Mechanistic rationale: In gastric fluid (pH 1.5-3.0, physiological [Cl⁻] ≈ 100-150 mM), the presence of excess chloride ions drives the equilibrium:

Mg²⁺ + 2Cl⁻ ⇌ MgCl₂(aq)

This prevents magnesium from forming insoluble magnesium-iron hydroxide complexes or competing for intestinal divalent metal transporter 1 (DMT1) binding sites. Pharmacokinetic studies in iron-deficient rats demonstrated that co-administration of 100 mg elemental iron (as FeSO₄) with 200 mg elemental magnesium (as MgO) plus 400 mg additional chloride (as MgCl₂) resulted in serum iron levels equivalent to iron-only supplementation (serum Fe: 180±15 μg/dL vs. 185±12 μg/dL, p>0.05), whereas magnesium-only formulations without chloride supplementation reduced iron absorption by 40-60% 13.

Clinical Applications In Combined Deficiency States

This formulation strategy is particularly valuable for patient populations with concurrent iron and magnesium deficiencies, including:

  • Pregnant women: Requiring 27 mg/day iron and 350-400 mg/day magnesium, where separate supplementation schedules reduce compliance
  • Chronic kidney disease patients: Exhibiting both anemia (requiring 100-200 mg/day elemental iron) and hypomagnesemia (requiring 300-600 mg/day magnesium)
  • Post-bariatric surgery patients: Experiencing malabsorption-induced deficiencies necessitating high-dose supplementation (200-300 mg/day iron, 400-800 mg/day magnesium) 13

Recommended dosing regimens involve twice-daily administration with meals to maximize gastric chloride availability and minimize gastrointestinal side effects. Formulations may include enteric coatings to delay release until the duodenum, where DMT1 expression is maximal, while maintaining sufficient chloride concentration through co-release of chloride salts 13.

Industrial Production Processes And Quality Control For Pharmaceutical Iron Chloride

Large-scale pharmaceutical iron chloride production must balance efficiency, purity, and regulatory compliance. Several industrial methodologies have been developed to address these requirements 2,3,7,11.

Spray Atomization Process For Anhydrous Iron Chloride

An early but still relevant process involves atomizing waste pickle liquor (ferrous chloride solutions from steel pickling operations) in a hot air stream within a refractory-lined tower 2. Key process parameters include:

  • Atomization conditions: Pickle liquor (20-40% FeCl₂) is pressurized to 3-6 bar and atomized through multiple nozzles (orifice diameter 0.5-2 mm) to generate droplets of 50-200 μm diameter
  • Drying tower specifications: Tower height 8-15 m, diameter 2-4 m, lined with acid-resistant volvicstone or alumina refractory, insulated with mineral wool to maintain internal temperatures of 400-600°C
  • Hot air supply: Air preheated to 500-700°C enters at the tower base at flow rates of 5000-15000 m³/h, providing rapid evaporation and oxidation of ferrous to ferric chloride
  • Product collection: Anhydrous FeCl₃ powder (particle size 10-100 μm) is collected in a water-cooled reservoir, while vapors pass through a condenser and scrubber system to recover HCl 2

This process yields pharmaceutical-grade anhydrous FeCl₃ with purity >97%, suitable for further purification or direct formulation into topical hemostatic agents. Typical production capacity ranges from 500-2000 kg/day per tower unit 2.

Chlorination Of Iron Phosphate Compounds For High-Purity Applications

The previously described iron phosphate chlorination process 5,6,9 offers superior purity for injectable pharmaceutical applications. Detailed operational parameters include:

Reactor design: Rotary kiln or fluidized bed reactor constructed from Inconel 625 or Hastelloy C-276 alloys to withstand corrosive chloride vapors at elevated temperatures. Typical dimensions: length 3-8 m, diameter 0.5-1.5 m, with internal refractory lining (alumina or silicon carbide) 5.

Feedstock preparation: Iron phosphate materials (particle size 100-500 μm) are dry-mixed with alkali/alkaline earth chlorides in molar ratios of 1:1.5 to 1:3 (iron phosphate:chloride salt) to ensure complete conversion. Moisture content must be <0.5% to prevent HCl formation and equipment corrosion 5,6.

Reaction conditions:

  • Temperature: 600-900°C (optimum 700-800°C for FeCl₃ formation)
  • Atmosphere: Nitrogen or argon with <100 ppm O₂, flow rate 50-200 L/min
  • Residence time: 1-4 hours depending on particle size and temperature
  • Pressure: Slightly positive (1.1-1.3 bar) to prevent air ingress 5,6

Vapor recovery: Off-gas containing FeCl₃ vapor (concentration 50-200 g/m³) is passed through a series of condensers:

  • Primary condenser (250-300°C): Removes high-boiling impur
OrgApplication ScenariosProduct/ProjectTechnical Outcomes
LANXESS Deutschland GmbHSustainable pharmaceutical-grade iron chloride synthesis from circular economy feedstocks, particularly lithium iron phosphate battery recycling streams for iron supplementation formulations.Iron Chloride Production from LFP Battery RecyclingAchieves >92% iron chloride yield from lithium iron phosphate battery waste through vapor-phase separation at 600-800°C, eliminating heavy metal contamination risks and enabling pharmaceutical-grade purity (≥98%, <10 ppm heavy metals).
VERLA-PHARM ArzneimittelfabrikOral pharmaceutical formulations for patients with concurrent iron and magnesium deficiencies, including pregnant women, chronic kidney disease patients, and post-bariatric surgery patients requiring high-dose mineral supplementation.Iron-Magnesium Co-Supplementation FormulationEnables simultaneous iron and magnesium supplementation without compromising iron bioavailability through chloride ion optimization (≥2 molar equivalents Cl⁻ per Mg²⁺), maintaining serum iron levels equivalent to iron-only therapy (180±15 μg/dL vs 185±12 μg/dL).
Undisclosed (JP2010215549A)Cardioprotective therapy for acute myocardial infarction treatment, administered within 6 hours of coronary occlusion to preserve left ventricular ejection fraction and reduce post-MI heart failure incidence.Iron Chelator for Myocardial Infarction TherapyUtilizes 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid with high Fe²⁺/Fe³⁺ affinity (log K ≈20-22) to achieve 30-45% reduction in infarct size by preventing iron-catalyzed oxidative stress via Fenton reaction inhibition.
E.I. du Pont de Nemours and CompanyPurification of iron chloride derived from titanium dioxide production by-products for pharmaceutical formulations requiring stringent purity standards, particularly injectable iron therapies.High-Purity Iron Chloride Purification ProcessRemoves niobium, titanium, and zirconium impurities to <5 ppm through thermal hydrolysis at 120-300°C under autogenous pressure (2-15 bar), achieving pharmaceutical-grade specifications suitable for injectable applications.
Tioxide Group Services LimitedIndustrial-scale production of pharmaceutical-grade iron oxide from iron chloride by-products, applicable to topical hemostatic agents and iron oxide excipients for drug formulations.Iron Oxide Production via Fluidized Bed OxidationConverts ferric chloride to iron oxide and recovers chlorine through vapor-phase oxidation at 700-900°C in fluidized bed reactors with continuous particle recirculation, preventing equipment scaling and enabling efficient chlorine recovery.
Reference
  • Use of iron chelating agents for the treatment of myocardial infarction
    PatentInactiveJP2010526849A
    View detail
  • Improvements in the Manufacture of Iron Chloride.
    PatentInactiveGB100517A
    View detail
  • Process for producing iron chloride from iron phosphate compounds
    PatentPendingTW202506545A
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png